Profil Institute's CEO and Sr. Scientific Director Spearhead Publications Bridging Metabolic and Cardiovascular Treatments and Drug Development

SAN DIEGO, Oct. 4, 2012 /PRNewswire/ -- Profil Institute for Clinical Research, Inc., a specialized clinical research institute optimizing early phase diabetes, obesity and cardiometabolic drug development, announced today that Prof. Andrew J Krentz M.D., Senior Director of Scientific Services, has been appointed Editor-in-Chief of the online journal Cardiovascular Endocrinology (www.cardiovascularendocrinology.com).  The journal was officially launched this week at the European Association for the Study of Diabetes (EASD) meeting in Berlin.

Profil Institute also announced that Prof. Krentz, Prof. Lutz Heinemann Ph.D., Senior Scientific Consultant to Profil Institute, and Dr. Marcus Hompesch, Profil Institute's President and CEO, are authors of the forthcoming textbook Cardiometabolic Drugs - Research Methods for Early Clinical Development, to be published by Springer.

About the online journal Cardiovascular Endocrinology:

Cardiovascular Endocrinology publishes peer-reviewed research in cardiovascular disease, endocrinology, and metabolism with an emphasis on studies that demonstrate the interaction between these disciplines. The journal is designed to foster collaboration between cardiologists and endocrinologists in addressing diabetes, hypertension, dyslipidemia, and related diseases and conditions.

"We hope that Cardiovascular Endocrinology will provide an attractive new forum for clinicians and researchers active in these highly prevalent disorders where scientific and therapeutic developments can be shared," said Prof. Krentz.

Lippincott Williams & Wilkins, a division of Wolters Kluwer Health, publishes the journal, as well as a number of today's top-cited scientific journals, including the official journals of the American Heart Association.

About the forthcoming textbook Cardiometabolic Drugs - Research Methods for Early Clinical Development:

Cardiometabolic Drugs - Research Methods for Early Clinical Development will bridge metabolic and cardiovascular disease areas as they relate to early phase clinical research – the first time that a drug in development is tested in humans.  The book, which is expected in 2013, is to be published by Springer, a leading global scientific publisher whose journals include the official EASD journal Diabetologia.

"The textbook will focus on the powerful interplay and side-effect risks between metabolic and cardiovascular drug development and specific early phase research methods critical to predict clinical trial outcomes," said Dr. Hompesch.

"A scientific journal and textbook focusing specifically on cardiovascular disease as it relates to endocrinology and metabolism is long overdue," added Dr. Hompesch.  "The journal Cardiovascular Endocrinology is already generating a great deal of enthusiasm within the academic and clinical communities."

About Profil^® Institute for Clinical Research, Inc.

Profil Institute is internationally renowned as a Center of Excellence for early phase clinical research of drugs and devices for diabetes, obesity and related cardiometabolic diseases.  Through the company's scientific expertise, advanced clinical research methods, and proprietary technology, Profil Institute is able to provide a wider scope of services and execute studies of far more complexity for its clients. As such, Profil Institute has been involved with every clinically promising drug class in diabetes and in more than 175 clinical studies since the company's inception in 2004.  For more information visit www.profilinstitute.com. 

SOURCE Profil Institute for Clinical Research, Inc.